ASH: CAR T-Cell Therapy Promising for Relapsed/Refractory iNHL
WEDNESDAY, Dec. 9, 2020 -- Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, is promising for the treatment of relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), according to a study presented at the annual meeting of the American Society of Hematology, held virtually from Dec. 5 to 8.
Caron Jacobson, M.D., from the Dana Farber Cancer Institute in Boston, and colleagues presented the primary analysis of a phase 2 single-arm study of axi-cel in patients with R/R iNHL. A total of 146 patients with advanced-stage iNHL, including follicular lymphoma (FL; 124 patients) and marginal zone lymphoma (MZL; 22 patients) underwent leukapheresis followed by conditioning therapy and a single infusion of axi-cel. The primary end point was objective response rate (ORR).
The researchers found that the ORR was 92 percent among efficacy-evaluable patients with iNHL during a median follow-up of 17.5 months, with a 76 percent complete response rate. The ORR was 94 and 85 percent for patients with FL and MZL, respectively. Across key risk groups analyzed by FLIPI, POD24, GELF, refractory status, and prior lines of therapy, ORR was comparable. Overall, 62 percent of all treated patients had ongoing responses as of the data cutoff. Grade 3 or higher adverse events occurred in 86 percent of patients with iNHL, most commonly neutropenia, decreased neutrophil count, and anemia.
"We were very impressed with the magnitude of the responses, and also the durability. This treatment has meaningfully affected high-risk patients with these diseases," Jacobson said in a statement. "I was also struck early on by how favorable the safety profile was compared to what we've been seeing in the fast-growing lymphomas such as large B cell lymphoma."
Several authors disclosed financial ties to the pharmaceutical industry.
© 2021 HealthDay. All rights reserved.
Posted: December 2020
Read this next
FRIDAY, Nov. 20, 2020 -- For patients with primary central nervous system lymphoma (PCNSL), the incidence of venous thromboembolism (VTE) and major bleeding is high, according to...
MONDAY, July 20, 2020 -- Lymphoma survivors are at substantial long-term risk for chronic kidney disease (CKD) development, according to a study published online July 11 in...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.